#MEDIA: Announcing positive topline results from a Phase 3 trial evaluating our investigational CELMoD agent for adult patients with relapsed or refractory #MultipleMyeloma. https://t.co/6g55GwOGDk https://t.co/eP0UrHuSFW -
#MEDIA: Announcing positive topline results from a Phase 3 trial evaluating our investigational CELMoD agent for adult patients with relapsed or refractory #MultipleMyeloma. https://t.co/6g55GwOGDk https://t.co/eP0UrHuSFW -